Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study
被引:110
|
作者:
Amabile, Nicolas
论文数: 0引用数: 0
h-index: 0
机构:
Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Univ Paris 05, UMR S970, Paris, FranceParis Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Amabile, Nicolas
[1
,2
]
Guerin, Alain P.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris 05, UMR S970, Paris, France
Ctr Hosp Manhes, Dept Nephrol, Fleury Merogis, FranceParis Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Guerin, Alain P.
[2
,3
]
Tedgui, Alain
论文数: 0引用数: 0
h-index: 0
机构:
Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Univ Paris 05, UMR S970, Paris, FranceParis Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Tedgui, Alain
[1
,2
]
Boulanger, Chantal M.
论文数: 0引用数: 0
h-index: 0
机构:
Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Univ Paris 05, UMR S970, Paris, FranceParis Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Boulanger, Chantal M.
[1
,2
]
London, Gerard M.
论文数: 0引用数: 0
h-index: 0
机构:
Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
Univ Paris 05, UMR S970, Paris, France
Ctr Hosp Manhes, Dept Nephrol, Fleury Merogis, FranceParis Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
London, Gerard M.
[1
,2
,3
]
机构:
[1] Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
[2] Univ Paris 05, UMR S970, Paris, France
[3] Ctr Hosp Manhes, Dept Nephrol, Fleury Merogis, France
Background. Endothelial dysfunction in cardiovascular (CV) diseases is closely associated with increases in plasma level of shed membrane microparticles (MPs) of endothelial origin. As arterial damage is a major contributor to CV mortality, we examined whether or not increases in endothelial microparticles (EMPs) circulating levels could predict outcome in patients with end-stage renal disease (ESRD). Methods. This prospective pilot study conducted in a community hospital (median follow-up: 50.5 months), included 81 stable haemodialysed ESRD patients (59 +/- 14 years; 63% male). Platelet-free plasma obtained 72 h after last dialysis was analysed by flow cytometry, and MPs cellular origin identified as endothelial (CD31+CD41-MPs; EMPs), platelets (CD31+CD41-MPs) or erythrocyte (CD235a+MPs). The main outcome measures were global and CV mortality (fatal myocardial infarction, stroke, acute pulmonary oedema and sudden cardiac death). Results. Non-survivors (n = 24) were older (P < 0.001) and characterized by higher levels of EMPs (P < 0.01) and high-sensitivity C-reactive protein (P < 0.05) and lower diastolic blood pressure (P < 0.001). Kaplan-Meier analysis demonstrated significantly higher probability of all-cause (P < 0.001) and CV mortality (P < 0.0001) between the lower and upper EMPs tertiles. Multivariate Cox regression analysis demonstrated that baseline EMP levels independently predicted all-cause [hazard ratio (HR) = 21.7, 95% confidence interval (CI): 4.23-111.18 per log EMPs/mu L; P = 0.0002] and CV mortality (HR = 20.0, 95% CI: 3.86-103.5) per log EMPs/mu L; P < 0.0004) after adjustment for confounding factors. EMPs baseline level was a stronger predictor of poor outcome than classical risk factors. Conclusion. This study demonstrates that increased plasma levels of EMPs is a robust independent predictor of severe CV outcome in end-stage renal failure patients.